Curated News
By: NewsRamp Editorial Staff
July 06, 2026
Novartis Buys Myricx Bio for $1.1B, ADC Deal Frenzy Continues
TLDR
- Novartis's $1.1B acquisition of Myricx Bio highlights the value of next-gen ADC platforms like VERAXA's BiTAC.
- Novartis acquires Myricx Bio for its NMTi payload platform and two lead ADCs, with $1.1B upfront and $400M milestones.
- These ADC deals advance cancer therapies by enabling more targeted treatments with fewer side effects for patients.
- VERAXA's BiTAC platform spans both ADCs and TCEs, a rare combination attracting billions in pharma investments.
Impact - Why it Matters
This news matters because it highlights the accelerating pace of investment in antibody-drug conjugates (ADCs) and T-cell engagers, which are among the most promising frontiers in cancer therapy. For investors, companies like VERAXA Biotech that operate in these high-demand areas may see increased valuation and partnership opportunities. For patients, these deals signal that pharmaceutical companies are doubling down on innovative treatments that could lead to more effective and less toxic cancer therapies. The broader trend of multibillion-dollar acquisitions in this space underscores the strategic importance of differentiated antibody platforms, making it a key area to watch for both medical advancements and investment potential.
Summary
Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (“ADC”) technologies. The deal grants Novartis access to Myricx’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and two lead ADC programs, targeting limitations of existing cancer therapies. This marks the latest in a series of multibillion-dollar deals in the antibody therapeutics space, including Jazz Pharmaceuticals’ collaboration with AbCellera, Gilead Sciences’ acquisition of Tubulis, and multiple other ADC licensing agreements.
Against this backdrop, VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments. The company is advancing proprietary antibody therapeutics spanning both ADCs and T-cell engagers (“TCEs”) through its patented BiTAC platform. VERAXA is positioning itself within two therapeutic categories—ADCs and TCEs—that continue to attract significant pharmaceutical investment, strategic collaborations, and acquisition activity. The Novartis-Myricx deal underscores the industry’s hunger for differentiated antibody platforms that can improve upon existing cancer treatments.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is building a premier engine for next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company’s BiTAC platform and pipeline of ADCs and bispecifics are designed to address the growing demand for more effective and targeted cancer therapies. As major pharma continues to commit billions to this space, VERAXA’s focus on quality-by-design and transformative technologies positions it as a potential partner or acquisition target in the evolving oncology landscape.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Novartis Buys Myricx Bio for $1.1B, ADC Deal Frenzy Continues
